JP2013507394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507394A5 JP2013507394A5 JP2012533364A JP2012533364A JP2013507394A5 JP 2013507394 A5 JP2013507394 A5 JP 2013507394A5 JP 2012533364 A JP2012533364 A JP 2012533364A JP 2012533364 A JP2012533364 A JP 2012533364A JP 2013507394 A5 JP2013507394 A5 JP 2013507394A5
- Authority
- JP
- Japan
- Prior art keywords
- lactobacillus
- composition
- pharmaceutically acceptable
- composition according
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 43
- 239000006041 probiotic Substances 0.000 claims 9
- 230000000529 probiotic effect Effects 0.000 claims 9
- 235000018291 probiotics Nutrition 0.000 claims 9
- 244000005700 microbiome Species 0.000 claims 8
- 206010003805 Autism Diseases 0.000 claims 5
- 208000020706 Autistic disease Diseases 0.000 claims 5
- 208000029560 autism spectrum disease Diseases 0.000 claims 5
- 241000192001 Pediococcus Species 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 239000003429 antifungal agent Substances 0.000 claims 4
- 229940121375 antifungal agent Drugs 0.000 claims 4
- 230000003115 biocidal effect Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 241001608472 Bifidobacterium longum Species 0.000 claims 3
- 241000186660 Lactobacillus Species 0.000 claims 3
- 244000199866 Lactobacillus casei Species 0.000 claims 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims 3
- 240000006024 Lactobacillus plantarum Species 0.000 claims 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 235000013305 food Nutrition 0.000 claims 3
- 229940039696 lactobacillus Drugs 0.000 claims 3
- 229940017800 lactobacillus casei Drugs 0.000 claims 3
- 229940072205 lactobacillus plantarum Drugs 0.000 claims 3
- 239000000047 product Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 241000186000 Bifidobacterium Species 0.000 claims 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims 2
- 241000186012 Bifidobacterium breve Species 0.000 claims 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- 108010068370 Glutens Proteins 0.000 claims 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims 2
- 241000186612 Lactobacillus sakei Species 0.000 claims 2
- 241000186869 Lactobacillus salivarius Species 0.000 claims 2
- 241000191998 Pediococcus acidilactici Species 0.000 claims 2
- 241000500340 Pediococcus damnosus Species 0.000 claims 2
- 241000235070 Saccharomyces Species 0.000 claims 2
- 241000194020 Streptococcus thermophilus Species 0.000 claims 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims 2
- 229940004120 bifidobacterium infantis Drugs 0.000 claims 2
- 229940009289 bifidobacterium lactis Drugs 0.000 claims 2
- 239000005018 casein Substances 0.000 claims 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims 2
- 235000021240 caseins Nutrition 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 2
- 230000001332 colony forming effect Effects 0.000 claims 2
- 235000021312 gluten Nutrition 0.000 claims 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000013406 prebiotics Nutrition 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 241000193749 Bacillus coagulans Species 0.000 claims 1
- 241000194108 Bacillus licheniformis Species 0.000 claims 1
- 244000063299 Bacillus subtilis Species 0.000 claims 1
- 235000014469 Bacillus subtilis Nutrition 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241001134770 Bifidobacterium animalis Species 0.000 claims 1
- ADBHAJDGVKLXHK-UHFFFAOYSA-N Casomorphin Chemical compound CCC(C)C(C(O)=O)NC(=O)C1CCCN1C(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C1N(CCC1)C(=O)C(N)CC=1C=CC(O)=CC=1)CC1=CC=CC=C1 ADBHAJDGVKLXHK-UHFFFAOYSA-N 0.000 claims 1
- 108010049140 Endorphins Proteins 0.000 claims 1
- 102000009025 Endorphins Human genes 0.000 claims 1
- 108010092674 Enkephalins Proteins 0.000 claims 1
- 241000194033 Enterococcus Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229920001503 Glucan Polymers 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- 240000001929 Lactobacillus brevis Species 0.000 claims 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims 1
- 241001134659 Lactobacillus curvatus Species 0.000 claims 1
- 241000500356 Lactobacillus dextrinicus Species 0.000 claims 1
- 241000186840 Lactobacillus fermentum Species 0.000 claims 1
- 241000186606 Lactobacillus gasseri Species 0.000 claims 1
- 240000002605 Lactobacillus helveticus Species 0.000 claims 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims 1
- 241000186605 Lactobacillus paracasei Species 0.000 claims 1
- 241000866650 Lactobacillus paraplantarum Species 0.000 claims 1
- 241000186684 Lactobacillus pentosus Species 0.000 claims 1
- 241000186604 Lactobacillus reuteri Species 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims 1
- 241000192129 Leuconostoc lactis Species 0.000 claims 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 claims 1
- 241001468196 Leuconostoc pseudomesenteroides Species 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 241001471187 Patu Species 0.000 claims 1
- 241000529920 Pediococcus parvulus Species 0.000 claims 1
- 241000191996 Pediococcus pentosaceus Species 0.000 claims 1
- 229920000294 Resistant starch Polymers 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 244000057717 Streptococcus lactis Species 0.000 claims 1
- 235000014897 Streptococcus lactis Nutrition 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940054340 bacillus coagulans Drugs 0.000 claims 1
- 229940118852 bifidobacterium animalis Drugs 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims 1
- 235000019219 chocolate Nutrition 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 235000011950 custard Nutrition 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 102000038379 digestive enzymes Human genes 0.000 claims 1
- 108091007734 digestive enzymes Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims 1
- 229940107187 fructooligosaccharide Drugs 0.000 claims 1
- 235000013569 fruit product Nutrition 0.000 claims 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims 1
- 150000003271 galactooligosaccharides Chemical class 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 235000011868 grain product Nutrition 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- 229940012969 lactobacillus fermentum Drugs 0.000 claims 1
- 229940054346 lactobacillus helveticus Drugs 0.000 claims 1
- 229940001882 lactobacillus reuteri Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 235000011962 puddings Nutrition 0.000 claims 1
- 230000001373 regressive effect Effects 0.000 claims 1
- 235000021254 resistant starch Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 235000020195 rice milk Nutrition 0.000 claims 1
- 229960002181 saccharomyces boulardii Drugs 0.000 claims 1
- 235000015067 sauces Nutrition 0.000 claims 1
- 235000013322 soy milk Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25022009P | 2009-10-09 | 2009-10-09 | |
| US61/250,220 | 2009-10-09 | ||
| PCT/US2010/052076 WO2011044516A2 (en) | 2009-10-09 | 2010-10-08 | Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015255700A Division JP2016084352A (ja) | 2009-10-09 | 2015-12-28 | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013507394A JP2013507394A (ja) | 2013-03-04 |
| JP2013507394A5 true JP2013507394A5 (https=) | 2013-11-28 |
Family
ID=43857421
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012533364A Pending JP2013507394A (ja) | 2009-10-09 | 2010-10-08 | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
| JP2015255700A Pending JP2016084352A (ja) | 2009-10-09 | 2015-12-28 | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
| JP2017195604A Pending JP2018027972A (ja) | 2009-10-09 | 2017-10-06 | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015255700A Pending JP2016084352A (ja) | 2009-10-09 | 2015-12-28 | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
| JP2017195604A Pending JP2018027972A (ja) | 2009-10-09 | 2017-10-06 | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110091431A1 (https=) |
| EP (2) | EP2485744A4 (https=) |
| JP (3) | JP2013507394A (https=) |
| CA (1) | CA2774963A1 (https=) |
| WO (1) | WO2011044516A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BG66608B1 (bg) * | 2011-05-04 | 2017-10-16 | "Ел Би Булгарикум" ЕАД | Полибактериален пробиотичен препарат |
| US9579353B2 (en) | 2011-06-10 | 2017-02-28 | Prothera, Inc. | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes |
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| WO2014036182A2 (en) | 2012-08-29 | 2014-03-06 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
| WO2015175926A1 (en) * | 2014-05-15 | 2015-11-19 | Children's Medical Center Corporation | Systems and methods for identifying neurobiological biomarkers using eeg |
| WO2016069801A1 (en) | 2014-10-30 | 2016-05-06 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodecelopmental disorders |
| EA201790811A1 (ru) | 2014-10-30 | 2017-11-30 | Калифорния Инститьют Оф Текнолоджи | Содержащие бактерии композиции и способы для улучшения видов поведения при нарушениях неврологического развития |
| AU2016268158B2 (en) | 2015-05-22 | 2022-03-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| SMT202300283T1 (it) | 2016-04-15 | 2023-11-13 | Baylor College Medicine | Lactobacillus reuteri mm4-1a per l’uso nel trattamento o nella prevenzione dei disturbi dello spettro autistico |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US11959125B2 (en) | 2016-09-15 | 2024-04-16 | Sun Genomics, Inc. | Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample |
| US10428370B2 (en) | 2016-09-15 | 2019-10-01 | Sun Genomics, Inc. | Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample |
| US20200023018A1 (en) * | 2017-02-07 | 2020-01-23 | California Institute Of Technology | Modulation of gut microbiota in huntington's disease and rett syndrome |
| US20210100853A1 (en) * | 2017-03-28 | 2021-04-08 | Morinaga Milk Industry Co., Ltd. | Composition for Degrading Opioid Peptide |
| WO2019032573A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER |
| US20210128567A1 (en) * | 2017-08-29 | 2021-05-06 | Flaask, Llc | Compositions and Methods for Cognitive, Immune and Digestive Support in Patients with Autism Spectrum Disorder |
| WO2019075456A2 (en) | 2017-10-13 | 2019-04-18 | Locus Ip Company, Llc | METHODS AND SUBSTANCES FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES |
| KR102218992B1 (ko) * | 2017-12-12 | 2021-02-23 | 한국생명공학연구원 | 아가토바쿨룸 속 균주를 유효성분으로 함유하는 자폐 범주성 장애의 예방, 개선 또는 치료용 조성물 |
| EP3768287A2 (en) * | 2018-03-22 | 2021-01-27 | Adare Pharmaceuticals SAS | New use of microbiological compositions |
| CN109172615A (zh) * | 2018-09-07 | 2019-01-11 | 北京金锋实验室科技有限公司 | 用于治疗自闭症患者的益生菌 |
| US12083152B2 (en) | 2018-09-26 | 2024-09-10 | Meiji Co., Ltd. | Agent for improving mitochondrial function |
| CA3116010A1 (en) * | 2018-10-26 | 2020-04-30 | Sun Genomics Inc. | Universal method for extracting nucleic acid molecules from a diverse population of microbes |
| US12582148B2 (en) | 2019-01-25 | 2026-03-24 | Flaask, Llc | Compositions and methods for improving quality of life in patients with autism spectrum disorder |
| US12290538B2 (en) | 2019-07-19 | 2025-05-06 | Finch Therapeutics Holdings Llc | Methods and products for treatment of gastrointestinal disorders |
| JP6739602B1 (ja) * | 2019-07-24 | 2020-08-12 | 雪印メグミルク株式会社 | 記憶・学習能維持および／または向上用組成物及び組成物を含む食品、医薬品、飼料 |
| US20230033606A1 (en) * | 2019-12-17 | 2023-02-02 | Metagenics, Inc. | Multi-strain probiotic composition and its use |
| JP2023511275A (ja) * | 2020-01-13 | 2023-03-17 | サイオート バイオサイエンシーズ， インコーポレイテッド | 自閉症および関連障害を処置または改善するための方法 |
| WO2021155543A1 (en) * | 2020-02-06 | 2021-08-12 | Lee Wang Tso | Composition of lactic acid bacterium for use in preventing or treating rett syndrome |
| TWI770463B (zh) * | 2020-02-06 | 2022-07-11 | 國立臺灣大學 | 用於預防或治療雷特氏症的乳酸菌組成物 |
| RU2733713C1 (ru) * | 2020-02-11 | 2020-10-06 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ прогнозирования эффективности коррекции поведенческих расстройств у детей с аутизмом при соблюдении безглютеновой диеты |
| WO2021161205A1 (en) * | 2020-02-13 | 2021-08-19 | Eyal Research Consultants Ltd | Microbial combinations with modulators of the opioid system and uses thereof |
| CN111455076B (zh) * | 2020-04-17 | 2022-10-21 | 济南市儿童医院 | 用于儿童孤独症评估的口腔菌群微生物 |
| CA3200656A1 (en) * | 2020-11-12 | 2022-05-19 | Synbiotics Ab | Synbiotic composition |
| CN116867484A (zh) * | 2020-12-09 | 2023-10-10 | 克莱斯通公司 | 用于治疗孤独症谱系障碍的方法和化合物 |
| CN113018318A (zh) * | 2021-01-19 | 2021-06-25 | 北京科拓恒通生物技术股份有限公司 | 乳双歧杆菌Probio-M8及其制品用于制备治疗ASD药物的用途 |
| CN112852670B (zh) * | 2021-01-26 | 2022-08-09 | 青岛东海药业有限公司 | 一种婴儿双歧杆菌dh231及其发酵产物、应用和微生态制剂 |
| WO2022171203A1 (zh) * | 2021-02-10 | 2022-08-18 | 中科微智（北京）生物科技有限公司 | 一种乳双歧杆菌及其应用 |
| CN115919907A (zh) | 2021-08-31 | 2023-04-07 | E·施约林 | 一种用于治疗和/或预防食物和/或酒精中毒的组合物 |
| CN117918526B (zh) * | 2023-12-01 | 2026-04-17 | 山东省大健康精准医疗产业技术研究院 | 一种孤独症谱系障碍改善剂及其制备方法与应用 |
| CN117431190B (zh) * | 2023-12-14 | 2024-03-12 | 深圳未知君生物科技有限公司 | 一株能够缓解自闭症谱系障碍的短双歧杆菌及其应用 |
| EP4670726A1 (en) * | 2024-06-28 | 2025-12-31 | N.V. Nutricia | COMPOSITION TO IMPROVE INTESTINAL HEALTH ASSOCIATED WITH A STATE OF THE INTESTINAL-BRAIN AXIS |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716615A (en) * | 1992-02-10 | 1998-02-10 | Renata Maria Anna Cavaliere Vesely | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
| EP0574681A1 (en) * | 1992-06-15 | 1993-12-22 | Quest International B.V. | Yogurt product containing bacteriocin from pediococcus adilactici |
| AUPM823094A0 (en) * | 1994-09-16 | 1994-10-13 | Goodman Fielder Limited | Probiotic compositions |
| US6241983B1 (en) | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
| US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| IT1288119B1 (it) * | 1996-06-28 | 1998-09-10 | Renata Maria Anna Ve Cavaliere | Composizioni dietetiche da utilizzare nell'alimentazione per via enterica |
| CN1254256A (zh) * | 1997-03-24 | 2000-05-24 | 维微亚美国交易股份有限公司 | 稳定的固体细菌组合物 |
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| EP0931543B1 (de) * | 1997-12-19 | 2002-03-20 | MERCK PATENT GmbH | Mehrschichttablette enthaltend probiotische Mikroorganismen wie z.B. Lactobacilli oder Bifidobakterien |
| US6203797B1 (en) * | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| US6410527B1 (en) * | 1998-03-02 | 2002-06-25 | Schering Corporation | Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism |
| US5902743A (en) * | 1998-03-20 | 1999-05-11 | Wisconsin Alumni Research Foundation | Probiotic bifidobacterium strain |
| US6368591B2 (en) * | 1998-05-15 | 2002-04-09 | Shanghai Sine Pharmaceutical Corporation Ltd. | Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof |
| US6080401A (en) * | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
| NL1010770C2 (nl) * | 1998-12-09 | 2000-06-13 | Nutricia Nv | Preparaat dat oligosacchariden en probiotica bevat. |
| ID29150A (id) * | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| EP1034788A1 (en) * | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactic acid bacteria strains capable of preventing diarrhea |
| CN1244684C (zh) * | 1999-03-11 | 2006-03-08 | 雀巢制品公司 | 能够预防病原细菌和轮状病毒引起的腹泻的乳杆菌菌株 |
| US6468525B1 (en) * | 1999-08-10 | 2002-10-22 | Renew Life, Inc. | Probiotic formulation |
| US6251391B1 (en) * | 1999-10-01 | 2001-06-26 | Klaire Laboratories, Inc. | Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons |
| US6447772B1 (en) | 1999-10-01 | 2002-09-10 | Klaire Laboratories, Inc. | Compositions and methods relating to reduction of symptoms of autism |
| US6271983B1 (en) * | 1999-11-05 | 2001-08-07 | Storage Technology Corporation | Rotary access port for automated tape library |
| AU2001233529A1 (en) * | 2000-02-10 | 2001-08-20 | Andrew W. Bruce | Probiotic therapy for newborns |
| US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| US20020013270A1 (en) | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
| US20040062757A1 (en) * | 2001-06-05 | 2004-04-01 | Finegold Sydney M. | Method of testing gastrointestinal diseases associated with species of genus clostridium |
| FI110668B (fi) * | 2000-06-20 | 2003-03-14 | Aboatech Ab Oy | Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn |
| JP3944076B2 (ja) * | 2000-08-25 | 2007-07-11 | わかもと製薬株式会社 | 乳酸菌含有プロバイオティクス製品 |
| AU2002236527A1 (en) * | 2000-11-30 | 2002-06-11 | The Health Research Institute | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| DE10162518A1 (de) * | 2000-12-20 | 2002-08-08 | Sumitomo Chemical Co | Harzmasse, Laminat und Herstellung des Laminats |
| EA009780B1 (ru) * | 2001-06-19 | 2008-04-28 | Норберт Мюллер | Применение ингибиторов cox-2 для лечения шизофрении, аффективных расстройств или осложнений, связанных с тиком |
| US20030092163A1 (en) * | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| US7101565B2 (en) * | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
| ITMI20020399A1 (it) * | 2002-02-28 | 2003-08-28 | Ct Sperimentale Del Latte S P | Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici |
| US6585996B1 (en) * | 2002-03-13 | 2003-07-01 | Westlake Laboratories, Inc. | Lipid-soluble thiamine derivatives in the treatment of autism |
| DK1485463T3 (da) * | 2002-03-21 | 2008-11-10 | Bifodan As | Lactobacillus stamme |
| WO2003082217A2 (en) * | 2002-03-29 | 2003-10-09 | Repligen Corporation | Ctla4 compositions in the treatment of autism |
| US20040092589A1 (en) * | 2002-06-21 | 2004-05-13 | Liisa Neumann | Use of retinoic acid for treatment of autism |
| US20040005304A1 (en) | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
| EP1556068B1 (en) * | 2002-10-03 | 2010-08-18 | Neuropharmacology Services, LLC | Oxytocin for use in the treatment of Autism and Asperger's disorder |
| FR2848115B1 (fr) * | 2002-12-05 | 2005-03-25 | Rhodia Chimie Sa | Composition de bacteries et son utilisation |
| US7122370B2 (en) * | 2003-01-14 | 2006-10-17 | Randolph Stanley Porubcan | Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life |
| US20060233777A1 (en) * | 2003-04-01 | 2006-10-19 | Andrea Piva | Use of bacteriocin for the amelioration of digestive functionality |
| SE527555C2 (sv) * | 2003-04-04 | 2006-04-11 | Probi Ab | Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar |
| US20070098705A1 (en) * | 2003-05-22 | 2007-05-03 | Symbiotics Ab | Probiotic composition comprising at least two lactic acid bacterial strains which are able to clonise the gatrointestonal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and fiber fermenting property |
| EP1633378A2 (en) * | 2003-06-13 | 2006-03-15 | N.V. Nutricia | Pediocin-producing pediococci |
| US20060177424A1 (en) * | 2003-08-29 | 2006-08-10 | Cobb Mark L | Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions |
| US7731976B2 (en) * | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| US7749509B2 (en) | 2003-08-29 | 2010-07-06 | Cobb And Company, Llp | Treatment of autism using probiotic composition |
| US7759105B2 (en) * | 2003-08-29 | 2010-07-20 | Cobb & Company, Llp | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
| US8871266B2 (en) * | 2003-10-01 | 2014-10-28 | Commonwealth Scientific & Industrial Research Organisation | Probiotic storage and delivery |
| CN101001635A (zh) * | 2003-12-04 | 2007-07-18 | 生物膜策略公司 | 预防生物膜形成、减少现有生物膜和减少细菌群的方法和组合物 |
| US20050130288A1 (en) * | 2003-12-11 | 2005-06-16 | Eromlife Co., Ltd. | Novel microorganism Pediococcus pentosaceus EROM101, having immune enhancement, anticancer and antimicrobial activities |
| US7252957B2 (en) * | 2004-02-03 | 2007-08-07 | Immunosciences Lab., Inc. | Identification of etiology of autism |
| SE0400355D0 (sv) * | 2004-02-17 | 2004-02-17 | Synbiotics Ab | New synbiotec use |
| US20050186188A1 (en) * | 2004-02-19 | 2005-08-25 | Peilin Guo | Compositions containing probiotics and polysaccharides and methods of use |
| US7456224B2 (en) * | 2004-04-05 | 2008-11-25 | Forest Laboratories Holdings, Ltd. | Method for treating autism |
| US20050276806A1 (en) * | 2004-06-15 | 2005-12-15 | Advanced Biotherapy, Inc. | Treatment of autism |
| MXPA06015184A (es) * | 2004-06-23 | 2007-11-22 | Nestec Sa | Procedimiento y composiciones utiles para prevenir y/o tratar pieles sensibles y/o secas. |
| US7935334B2 (en) | 2005-07-07 | 2011-05-03 | Imagilin Technologies, LLC | Probiotics as alternative medicines against infectious diseases |
| US20060008511A1 (en) * | 2004-07-08 | 2006-01-12 | Jhy-Jhu Lin | Probiotic products for pet applications |
| US20060020037A1 (en) * | 2004-07-22 | 2006-01-26 | Allergan, Inc. | Tazarotenic acid and esters thereof for treating autism |
| WO2006037922A1 (fr) * | 2004-10-04 | 2006-04-13 | L'oreal | Composition cosmetique et/ou dermatologique pour peaux sensibles |
| US20060269508A1 (en) * | 2005-03-29 | 2006-11-30 | Trejo Amy V | Means for regulating the cosmetic appearance and/or health of human keratinous tissue |
| AU2006235307B2 (en) * | 2005-04-08 | 2011-07-14 | Alimentary Health Ltd | Methods of use of orally administered probiotic Bifidobacteria for human beauty benefits |
| US20070092501A1 (en) * | 2005-04-26 | 2007-04-26 | Prothera, Inc. | Compositions and methods relating to reduction of symptoms of autism |
| WO2007081981A2 (en) * | 2006-01-11 | 2007-07-19 | Attune Foods | Probiotic food, process for its preparation and dietary regimen |
| US20070191440A1 (en) * | 2006-01-25 | 2007-08-16 | Solomon Michael E | Methods of treating autism and fragile X syndrome |
-
2010
- 2010-10-08 EP EP10822796.8A patent/EP2485744A4/en not_active Ceased
- 2010-10-08 JP JP2012533364A patent/JP2013507394A/ja active Pending
- 2010-10-08 EP EP17181229.0A patent/EP3260126A1/en not_active Withdrawn
- 2010-10-08 WO PCT/US2010/052076 patent/WO2011044516A2/en not_active Ceased
- 2010-10-08 US US12/901,225 patent/US20110091431A1/en not_active Abandoned
- 2010-10-08 CA CA2774963A patent/CA2774963A1/en not_active Abandoned
-
2015
- 2015-12-28 JP JP2015255700A patent/JP2016084352A/ja active Pending
-
2017
- 2017-10-06 JP JP2017195604A patent/JP2018027972A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507394A5 (https=) | ||
| CA2837479C (en) | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes | |
| Adams | Safety of industrial lactic acid bacteria | |
| US20200121740A1 (en) | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes | |
| US20110091431A1 (en) | Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease | |
| EP3542807A1 (en) | Composition comprising n-acetylcysteine and probiotic bacteria capable of restoring the stomach's own barrier effect which is lost during treatment of gastric hyperacidity with proton pump inhibitors | |
| HK1232148A1 (zh) | 用於减轻绝经後女性的腹痛的动物双歧杆菌乳酸亚种 | |
| JP3215992U (ja) | プロバイオティクスを含むチョコレート製品 | |
| Ozcan et al. | The use of prebiotics of plant origin in functional milk products | |
| US20250262255A1 (en) | Lactobacilli for treating cardiac dysfunction | |
| US10471110B2 (en) | Bifidobacteria for treating cardiac conditions | |
| Vijaya Kumar et al. | Beneficial effects of probiotics and prebiotics on human health | |
| Doğan et al. | Probiotics from food products and gastrointestinal health | |
| Lee et al. | Recent Research Trends and Future Perspectives of Lactic Acid Bacteria | |
| HK40020295A (en) | Pharmaceutical compositions containing pediococcus for reducing the symptoms of gastroenterological syndromes | |
| CN121693337A (zh) | 制剂组合物 | |
| JPWO2023099579A5 (https=) | ||
| Solanki et al. | Emerging Trends of Probiotics in Formulation Development as a Biotherapeutics Agent | |
| Sarkar | Postbiotics: Potential as functional ingredients—A review. Food Nutrition Chemistry. 2024; 2 (3): 241 |